TransMedics Group, Inc. $TMDX Shares Acquired by Citigroup Inc.

Citigroup Inc. boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 29.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,785 shares of the company’s stock after purchasing an additional 17,414 shares during the quarter. Citigroup Inc. owned about 0.22% of TransMedics Group worth $8,615,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Amalgamated Bank increased its stake in TransMedics Group by 0.8% in the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after purchasing an additional 80 shares during the period. Canada Pension Plan Investment Board grew its holdings in shares of TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after buying an additional 100 shares during the last quarter. Smartleaf Asset Management LLC increased its position in TransMedics Group by 24.5% in the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock valued at $72,000 after acquiring an additional 108 shares during the period. State of Wyoming increased its position in TransMedics Group by 20.9% in the 3rd quarter. State of Wyoming now owns 683 shares of the company’s stock valued at $77,000 after acquiring an additional 118 shares during the period. Finally, TD Waterhouse Canada Inc. raised its stake in TransMedics Group by 26.5% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 601 shares of the company’s stock valued at $69,000 after acquiring an additional 126 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Needham & Company LLC increased their price objective on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group upped their price target on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Oppenheimer lifted their price objective on shares of TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Piper Sandler boosted their price objective on shares of TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $150.67.

Insider Buying and Selling

In other news, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the sale, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. The trade was a 5.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Weill sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares of the company’s stock, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Stock Performance

Shares of TMDX opened at $145.26 on Monday. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. TransMedics Group, Inc. has a 52-week low of $62.07 and a 52-week high of $156.00. The company has a 50-day simple moving average of $133.80 and a 200-day simple moving average of $126.37. The company has a market capitalization of $4.98 billion, a PE ratio of 29.64 and a beta of 1.98.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.